Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosis
Choi, Jinkuk , Gao, Jie , Kim, Jaekwang , Kim, Jungsu , Tontonoz, Peter , Hong, Cynthia , Kim, Jungsu

Science Translational Medicine | November 18, 2015 | Volume: 7 | Issue: 314 | Pages: No page available

10.1126/scitranslmed.aad1904 | PMID 26582899 Get It

Inhibiting the E3 ubiquitin ligase Idol in a mouse model of Alzheimer’s-like pathology ameliorates disease severity by promoting clearance of Aβ peptides by microglia.
Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group
Mascarenhas, Leo , Felgenhauer, Judy, Bond, Mason, Villaluna, Doojduen, Femino, Joseph D. , Ranganathan, Sarangarajan , Meyer, James S., Womer, Richard B. , Görlick, Richard , Krailo, Mark , Marina, Neyssa , Laack, Nadia N. , Mascarenhas, Leo , Gorlick, Richard , Marina, Neyssa

Pediatric Blood & Cancer | November 18, 2015 | Volume: 63 | Issue: 3 | Pages: 493-498

10.1002/pbc.25837 | PMID 26579879 Get It

Female Sexual Function Improves After Endometrial Ablation
Marnach, Mary L. , Long, Margaret E. , McGree, Michaela E. , Weaver, Amy L. , Casey, Petra M.

Journal of Women's Health | November 18, 2015 | Volume: 25 | Issue: 2 | Pages: 149-154

10.1089/jwh.2015.5309 | PMID 26579584 Get It

Background: Many women have heavy menstrual bleeding during perimenopause that may interfere with overall quality of life and contribute to sexual dysfunction. We aimed to determine whether sexual function in women improves after endometrial ablation for heavy menstrual periods. Methods: Validated surveys (Female Sexual Function Index [FSFI], Female Sexual Distress Scale [FSDS], and Short-Form Health Survey [SF–12]) were administered to 136 women before and after endometrial ablation from August 2008 through June 2013. Scores at baseline and 6 months after surgery were compared using the paired t test. Results: A total of 97 women completed the FSFI and FSDS surveys at baseline and 6 months after ablation. Mean full-scale FSFI score increased from 26.5 to 28.8 ( p < .001), with improvement in 5 of 6 FSFI domains. Mean FSDS score decreased from 13.6 to 9.7 ( p < .001), showing decreased personal distress regarding sexual function. In assessing quality of life, SF–12 scores improved for global physical function ( p < .001) and mental function ( p = .002). Conclusions: Female sexual function improved and personal distress associated with sexual function decreased after endometrial ablation for heavy menstrual cycles.
Tunable tissue scaffolds fabricated by in situ crosslink in phase separation system
Liu, Xifeng , Chen, Wenjian , Gustafson, Carl T., Waletzki, Brian E., Yaszemski, Michael J. , Lu, Lichun , Miller, A. Lee , Miller, Alan Lee

RSC Advances | November 18, 2015 | Volume: 5 | Issue: 122 | Pages: 100824-100833

10.1039/c5ra19406g | PMID 26989479 Get It

A combined method by in situ crosslink polymers under phase separation condition was developed for tunable 3-D porous scaffolds fabrication.
Azacitidine with or without Entinostat for the treatment of therapy‐related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study
Prébet, Thomas , Sun, Zhuoxin , Ketterling, Rhett P. , Zeidan, Amer M. , Greenberg, Peter L. , Herman, James G. , Malick, Lisa, Paietta, Elisabeth , Czader, Magdalena , Figueroa, María E. , Gabrilove, Janice , Tallman, Martin S. , Litzow, Mark R. , Gore, Steven D. , intergroup, the Eastern Cooperative Oncology Group and North American Leukemia, Juckett, Mark , Smith, Mitchell R. , Erba, Harry Paul , intergroup, the Eastern Cooperative Oncology Group and North American Leukemia, Prebet, Thomas , Ketterling, Rhett P , Zeidan, Amer M

British Journal of Haematology | November 18, 2015 | Volume: 172 | Issue: 3 | Pages: 384-391

10.1111/bjh.13832 | PMID 26577691 Get It

AbstractTherapy‐related myeloid neoplasms (tMN) are serious late effects of the treatment of cancer with poor response to conventional treatment. Azacitidine (AZA) has been used to treat patients with tMN but current data are retrospective. We present here 47 tMN patients prospectively enrolled as a specific cohort in the E1905 study. TheE1905 study was a randomized phase 2 study (NCT00313586) testing 10 d of AZA (50 mg/m2/d) +/− the histone deacetylase inhibitor entinostat (4 mg/m2/d PO day‐3 and day‐10). A total of 47 patients [29 therapy‐related myelosyspastic syndrome (t‐MDS) and 18 therapy‐related acute myeloid leukaemia (t‐AML)] were recruited to the study. 24 patients were treated with AZA monotherapy and 23 with AZA+entinostat. The median number of administered cycles was 4, significantly higher in patients treated with AZA (6 cycles vs. 3 cycles, P = 0·008). Haematological normalization rates were 46% in monotherapy and 17% in the combination arm. Median overall survivals were 13 and 6 months, respectively. The novel 50 * 10 schedule of azacitidine appears effective, with response rates, when given as single agent, comparable to those for patients with de novo MDS/AML treated on the same protocol. However, the combination of AZA and entinostat was associated with increased toxicity and could not be recommended for treatment of tMN.
S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors
Blanke, Charles D. , Rankin, Cathy, Corless, Christopher L. , Eary, Janet F. , Mulder, Karen , Okuno, Scott H. , Heinrich, Michael C. , George, Suzanne , Heinrich, Michael C

The Oncologist | November 18, 2015 | Volume: 20 | Issue: 12 | Pages: 1353-1354

10.1634/theoncologist.2015-0295 | PMID 26576593 Get It

Abstract Lessons Learned Despite having significant rationale, S0502 failed to accrue for a number of reasons. Vetting a trial first, with scientific experts and funding agencies, does not guarantee success, especially when dealing with a rare tumor and/or one with an existing highly effective therapy. In the present case, adding an intravenous drug to an oral medication as part of a regimen expected to be continued for many years likely decreased patient (and physician) convenience and, thus, interest in the study. Background. Imatinib mesylate, a potent inhibitor of the KIT and PDGFR tyrosine kinases, is highly effective in the treatment of advanced gastrointestinal stromal tumors (GISTs). However, most imatinib-treated tumors eventually become resistant, accounting for a median progression-free survival of 19–23 months. Expression of vascular endothelial growth factor (VEGF) correlates with poor prognosis in GIST; bevacizumab, a monoclonal antibody against VEGF, is effective in a variety of solid tumors. We postulated combination therapy with imatinib plus bevacizumab would benefit patients with advanced GIST, particularly those reliant on VEGFA-dependent angiogenesis. Methods. Patients with metastatic or surgically unresectable GIST were eligible for this phase III open-label clinical trial, S0502. At registration, patients were randomly assigned to either imatinib 400 mg (standard) or 800 mg (patients with exon 9 KIT mutations), or imatinib plus bevacizumab, 7.5 mg/kg i.v. every 3 weeks. Patients were treated to progression, symptomatic deterioration, unacceptable toxicity, treatment delay greater than 4 weeks, or patient choice to withdraw from the study. The primary objective was to determine whether the addition of bevacizumab to imatinib would improve progression-free survival (PFS) in first-line treatment of incurable GIST. Results. S0502 opened on April 15, 2008. As of fall 2009, only 12 patients from at least 178 eligible SWOG centers plus those participating through Cancer Trials Support Unit had been entered in the study. Despite an aggressive promotion scheme involving the other cooperative groups and a major GIST patient advocacy group, accrual remained slow. The trial was closed on October 1, 2009, having accrued only 2% of the 572 patients planned. No scientific conclusions were forthcoming because of the small number of patients entered in the study. Two patients of the 6 in the combination arm reported grade 3 toxicities, 1 with proteinuria and 1 with fatigue, upper gastrointestinal hemorrhage, and anemia. Conclusion. No conclusions may be drawn from this trial and, thus, the combination of imatinib plus bevacizumab cannot be recommended for use.
What Is the Optimal Sequence of Rescue Treatments for Attacks of Neuromyelitis Optica Spectrum Disorder?
Weinshenker, Brian G. , Weinshenker, Brian G

Annals of Neurology | November 17, 2015 | Volume: 79 | Issue: 2 | Pages: 204-205

10.1002/ana.24557 | PMID 26575334 Get It

Clinical spectrum of valosin containing protein (VCP)‐opathy
Kazamel, Mohamed , Sorenson, Eric J. , McEvoy, Kathleen M., Jones, Lyell K. , Leep‐Hunderfund, Andrea N., Mauermann, Michelle L. , Milone, Margherita , Hunderfund, Andrea N. Leep , Jones, Lyell K , Mauermann, Michelle L

Muscle & Nerve | November 17, 2015 | Volume: 54 | Issue: 1 | Pages: 94-99

10.1002/mus.24980 | PMID 26574898 Get It

ABSTRACTIntroduction: Valosin containing protein (VCP) mutations cause a rare disorder characterized by hereditary inclusion body myopathy, Paget disease of bone (PDB), and frontotemporal dementia (FTD) with variable penetrance. VCP mutations have also been linked to amyotrophic lateral sclerosis and Charcot‐Marie‐Tooth disease type 2. Methods: Review of clinical, serological, electrophysiological, and myopathological findings of 6 VCP‐opathy patients from 4 unrelated families. Results: Patients manifested muscle weakness between ages 40 and 53 years and developed predominant asymmetric limb girdle weakness. One patient had distal weakness at onset and co‐existing peripheral neuropathy. Another patient had PDB, 1 had mild cognitive deficits, and 1 had FTD. All patients had myopathic and neurogenic electromyographic findings with predominant neurogenic changes in 2. Rimmed vacuoles were infrequent, while neurogenic changes were prominent in muscle biopsies. Conclusions: VCP‐opathy is a multifaceted disorder in which myopathy and peripheral neuropathy can coexist. The electrophysiological and pathological neurogenic changes raise the possibility of coexisting motor neuron involvement. Muscle Nerve, 2015 Muscle Nerve 54: 94–99, 2016 Muscle Nerve 54: 94–99, 2016
ALS biomarkers for therapy development: State of the field and future directions
Benatar, Michael , Jeromin, Andreas, Rutkove, Seward B. , Atassi, Nazem , Bruijn, Lucie, Boylan, Kevin, Boylan, Khrista , Berry, James D.

Muscle & Nerve | November 17, 2015 | Volume: 53 | Issue: 2 | Pages: 169-182

10.1002/mus.24979 | PMID 26574709 Get It

Optimizing Patient‐centered Communication and Multidisciplinary Care Coordination in Emergency Diagnostic Imaging: A Research Agenda
Sabbatini, Amber K. , Merck, Lisa H. , Froemming, Adam T. , Vaughan, William P., Brown, Michael D. , Applegate, Kimberly E. , Comfere, Nneka I. , Hess, Erik P. , Sabbatini, Amber K

Academic Emergency Medicine | November 17, 2015 | Volume: 22 | Issue: 12 | Pages: 1427-1434

10.1111/acem.12826 | PMID 26575785 Get It

AbstractPatient‐centered emergency diagnostic imaging relies on efficient communication and multispecialty care coordination to ensure optimal imaging utilization. The construct of the emergency diagnostic imaging care coordination cycle with three main phases (pretest, test, and posttest) provides a useful framework to evaluate care coordination in patient‐centered emergency diagnostic imaging. This article summarizes findings reached during the patient‐centered outcomes session of the 2015 Academic Emergency Medicine consensus conference “Diagnostic Imaging in the Emergency Department: A Research Agenda to Optimize Utilization.” The primary objective was to develop a research agenda focused on 1) defining component parts of the emergency diagnostic imaging care coordination process, 2) identifying gaps in communication that affect emergency diagnostic imaging, and 3) defining optimal methods of communication and multidisciplinary care coordination that ensure patient‐centered emergency diagnostic imaging. Prioritized research questions provided the framework to define a research agenda for multidisciplinary care coordination in emergency diagnostic imaging.